Oramed Pharmaceuticals Inc. (ORMP) Earnings History
Annual and quarterly earnings data from 2003 to 2024
Loading earnings history...
ORMP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ORMP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -1176.8% | 412.3% |
| 2022 | 100.0% | -1502.0% | -1397.1% |
| 2021 | 100.0% | -896.2% | -822.7% |
| 2020 | 96.7% | -433.8% | -424.8% |
Download Data
Export ORMP earnings history in CSV or JSON format
Free sign-in required to download data
Oramed Pharmaceuticals Inc. (ORMP) Earnings Overview
As of May 8, 2026, Oramed Pharmaceuticals Inc. (ORMP) reported trailing twelve-month net income of -$24M, reflecting -435.7% year-over-year growth. The company earned $-0.57 per diluted share over the past four quarters.
Looking at the long-term picture, ORMP's historical earnings data spans multiple years. The company achieved its highest annual net income of $6M in fiscal 2023.
Oramed Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MNKD (-$24M net income, 1.7% margin), NRXP (-$38M net income, -2336.5% margin), PRAX (-$327M net income), ORMP has comparable earnings metrics. Compare ORMP vs MNKD →
ORMP Earnings vs Peers
Earnings metrics vs comparable public companies
ORMP Historical Earnings Data (2003–2024)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$19M | -445.8% | -$13M | $-0.47 | - | - |
| 2023 | $6M | +114.6% | -$16M | $0.14 | 412.3% | -1176.8% |
| 2022 | -$38M | -69.8% | -$41M | $-0.97 | -1397.1% | -1502.0% |
| 2021 | -$22M | -93.2% | -$24M | $-0.78 | -822.7% | -896.2% |
| 2020 | -$12M | +19.8% | -$12M | $-0.56 | -424.8% | -433.8% |
| 2019 | -$14M | -12.8% | -$15M | $-0.82 | -531.1% | -541.3% |
| 2018 | -$13M | -21.4% | -$14M | $-0.86 | -519.7% | -552.3% |
| 2017 | -$10M | +4.4% | -$11M | $-0.79 | -426.7% | -438.6% |
| 2016 | -$11M | -51.6% | -$10M | $-0.87 | -1710.5% | -1561.6% |
| 2015 | -$7M | -27.0% | -$7M | $-0.67 | - | - |
See ORMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ORMP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ORMP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonORMP — Frequently Asked Questions
Quick answers to the most common questions about buying ORMP stock.
Is ORMP growing earnings?
ORMP EPS fell to $-0.57, with earnings declining -435.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-24M.
What are ORMP's profit margins?
Oramed Pharmaceuticals Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ORMP's earnings?
ORMP earnings data spans 2003-2024. The declining earnings trend is -435.7% YoY. Historical data enables comparison across business cycles.